Streetbeat News

Earnings

HZO

MarineMax (NYSE:HZO) reported Q2 2024 adjusted EPS of $0.18, missing the $0.66 estimate, with sales of $582.9M also missing the $590.189M estimate. This represents a 2.20% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 10:46 am

LUV

Southwest Airlines reported Q1 2024 adjusted EPS of $(0.36), missing the $(0.34) estimate, with sales of $6.33B also missing the $6.42B estimate. This represents a 10.92% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 10:46 am

CARR

Carrier Global's shares are trading lower after the company reported mixed Q1 financial results and reduced its 2024 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 10:43 am

MBLY

Mobileye Global has reaffirmed its FY24 revenue forecast to be between $1.830 billion and $1.960 billion, closely aligning with the $1.90 billion estimate. Additionally, the company projects its FY24 adjusted operating income to range from $270 million to $360 million.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 10:43 am

CAT

Caterpillar's stock is trading lower following the release of their Q1 earnings report, which revealed higher-than-expected EPS but a miss on revenue forecasts.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 10:42 am

MRK

Merck's stock price increased following the announcement of its Q1 financial results, which exceeded expectations. Additionally, the company has raised its financial guidance for 2024, signaling confidence in its future performance.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 10:40 am

SAGE

Sage Therapeutics projects its cash reserves and funding will sustain operations until 2026, despite expecting a decline in ZULRESSO revenues. The company foresees a reduction in operating expenses in 2024 compared to 2023 and does not expect any further milestone payments from collaborations for the remainder of 2024. The introduction of ZURZUVAE in the U.S. for treating PPD is anticipated to further decrease ZULRESSO's revenues over time.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 10:40 am

TXT

Textron (NYSE:TXT) reported Q1 2024 adjusted EPS of $1.20, missing the $1.23 estimate, and sales of $3.135B, below the $3.295B estimate. This represents a 14.29% increase in EPS and a 3.67% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 10:40 am

IIIN

Insteel Industries anticipates increased business momentum in the second half of FY24, fueled by a seasonal rise in construction activity, ongoing recovery in customer demand, and a positive shift in the macroeconomic landscape.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 10:40 am

CBZ

CBIZ projects its FY24 revenue to grow by 7% to 9% and anticipates its adjusted EPS to be between $2.70 and $2.75, compared to the estimated $2.72.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 10:39 am